Pharma's Market
SPECIAL REPORT
MOST SHARED
- US Stocks Avoid Closing Down Over 1%, Again
- When Love and the Fed Collide
- How Rescuing Greece Could Destroy the World
- Commodities Next Week: Why Gas Prices Are Heading Toward $5 Per Gallon
- 2012: The Year of the Stock Picker
- Get Ready for $5 Gas This Year: Ex-Shell CEO
- Pauley Perrette's Southern Bakery a Hit in Manhattan
- Private Homebuilders: Dead Men Walking
- Why Greece Will Default, Leave the Euro Zone
- Apple’s Record Run: $500 Is a Magic Number
- In Search of America's ‘Hottest Forecasters’
- Dow vs. S&P 500: Which is a Better Investment?
- Mick Fleetwood on the MP3 ‘Dumbing Down’ of Music
- Avis on the Road to Strong Growth: Analyst
- Private Homebuilders: Dead Men Walking
- LinkedIn’s Growth Is Already Priced In: Analyst
- The Real Reason Behind Bank of America’s Rally
- 5 Hedge Funds’ Top Stocks Soar After 2011 Rout
- This Valentine’s Day Love Is Served on a Silver Platter
- We're Not Greece: Italian Prime Minister Monti
- Private Homebuilders in the US: Dead Men Walking
- Dividend Payout Could Hit Record Amount This Year
- With Investors So Bullish, Stock Pullback Must Be Ahead
- Is Bill Gross, PIMCO's Bond King, Losing His Touch?
- Why Saving Greece Could Destroy the World
- Apple’s Record Run: $500 Is a Magic Number
- Housing Still Hurting Consumers, Economy: Bernanke
- Get Ready for $5 Gas This Year: Ex-Shell CEO
RSS FEED
Cepheid: The Google of Biotech?
Text Size 
Reporter
 |
] . But that's not the only stock getting a new stratospheric price target by an analyst. Michael Shulman is not Bear Stearns--he writes a newsletter for subscribers called, "ChangeWave Biotech Investor" and he maintains a blog. And in his weekly message yesterday Shulman moved his price target on Cepheid [CPHD
Loading...
()
] from $40 to $110. Shulman owns the stock. Lightly-traded CPHD shares this morning out of the gate hit a new high of nearly 25 bucks, but have quickly cooled off a little. On CNBC's "Fast Money" last night, Pete Najarian also gave the stock a bullish mention. And CPHD has had a huge run-up over the past few months.
Explaining his $70 shift Shulman writes, "…no, I didn't have too much to drink while watching the baseball playoff games." He bases his call on the uptake of Cepheid's test for hospital staph infections which is rolling out in Veterans Administration hospitals. The test is also being required upon hospital admission in a few states and Shulman believes that within five years every hospital will be doing it. He writes, "…and that my friends is a $1.4 BILLION (the caps are his emphasis) opportunity!"
But Shulman claims that's not the main reason for his bullishness. He cites comments made at an investment conference last week where Cepheid said it's working on microRNA. That's the technology that Alnylam and Isis Pharmaceuticals recently formed a joint venture to explore. Shulman believes that eventually Cepheid could develop a way to do a blood test for solid-tumor cancers which he calls a "multi-billion dollar opportunity".
He is pounding the table on the stock. "Get in now, don't wait," he writes. "I see this stock currently around $24, hitting that $110 target price in three to five years. Wall Street is unaware of the microRNA and cancer diagnostics potential of Cepheid, but it is becoming more aware every day."
As a general rule, I wouldn't blog about a price target increase by an analyst. But like the $700 number for GOOG, $110 for CPHD is eye-catching.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes
